MTNB - Earnings call transcript Q4 2018 | Matinas BioPharma Holdings, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings and welcome to the Matinas BioPharma Quarterly Update Conference Call and Webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded. I would now like to turn the conference over to your host, Jenene Thomas, Investor Relations. Ms. begin. may you Thomas,

Jenene Thomas

listeners Good or BioPharma and and and quarterly I are intentions, and remind this Sherry. call statements during joining state forward-looking of may webcast. you the the uncertainties. time, management's our to like Matinas update beliefs, would risks remarks morning, you, made thank this expectations everyone hopes, for At that projections Thank involve conference These call future.

provisions pursuant statements Matinas federal of this actual Harbor are materially. the Forward-looking statements BioPharma's on differ and the made laws. based to forward-looking on expectations These results securities could Safe call are current

a As should reliance undue on place any result, statements. you forward-looking not

statements BioPharma These documents actual Securities Securities to could review section and Exchange Some of Commission. from that you filed and carefully. these the website. Company's the Exchange encourage in available the differ results of factors and periodic to reports discussed the with are website in We such the documents Matinas those Investors the cause forward-looking are materially contemplated Commission's by on

call Company's be remarks, the question-and-answer will the Following a opened up session. prepared for

Development Medical Joining Dr. Executive Officer; call to Officer. It Chief Jabbour, pleasure turn me Terry my today to Chief Officer; the Terry Jerry. Mannino, the Ferguson, over Matkovits, Kucinski, on Jerry Dr. Chief Raphael Chief Financial call are Officer; Chief Scientific Keith Dr. Officer; and is now

Jerry Jabbour

believe conditions. dialed we with a two call. in of based into value MATXXXX, asset, assets. a is Thank a potentially multi-billion-dollar is one have thought to you, the during cardiovascular update exciting could patients driver a I those cardiovascular the of for large good that the positioning number metabolic going most prevention tremendous no drug fact stories our simply, be I best-in-class Matinas be used all a MATXXXX and of we the made market. this that that we us. upon lead XXXX in Quite statement we are Jenene, to It's morning of potential to prescription-only There treatment beginning and to believe going question for At biotech for and year, our be in omega-X be best-in-class

advancing treatment aggressively indication supporting omega-X are pharmaceutical severe believe with this hypertriglyceridemia. drug X those a that during an we this is from the are morning's initial toward reason approved in We clearly call. Phase currently belief will highlight of this is and product that the differentiated products our We

be year. we package you believe on delivery If MATXXXX, In without XXXX immune potential addition some world it to deliver ago, facing acid we generating truly cell best-in-class small months a biggest of positioned why we’ve today, polymers and or much toxicity. inside actively think our challenges undesirable at changed molecules the response much and how incredible transformational look an it what is of innovative to a platform. back drug or we be delivery. How nucleic them more medicine we centers progress we a little pursuing has been unintended to has made, are If X also think a has Matinas here about the how do than

on XXXX the after today. His spark immediately some September MATXXXX update XX, everyone Board. along were rekindled our complementary Vice hold this and decision Outcomes That the with that we to important valuable we development veteran this XXXX. It walk LePore call, was Study disease. specifically cardiovascular asset. we’re for for for Patrick product, to believe our is key it REDUCE-IT us added to vision were REDUCE-IT to we omega-X where in for when of designed relaunch fortunate brought strategic began line we’ve group Chairman. validated nature the program had presence is to patients Right prescription-only through the the have data to waiting that, positive as of Given from highlights another yet attract. been the on to our we top announcement Vascepa's MATXXXX, industry The data announced enough highly impressive all to September

team, views advisory Ballantyne and program Following the added delivery truly our primary MATXXXX XX meaningful design reinforced an announcement, Dr. and on clinical stage, very early help of positioning Steering we at we to and important in in we at record valuable Immediately transactions, to meaningful Pharmaceutical and Christie role of our presented multiple CFO, PK/PD of our best-in-class brings a we pharma in expertise data together formulations a gene Matkovits, such going a veteran impressed. sale in the studies. platform Dr. The and the These November MATXXXX. overseeing continues transformational. XXXX, as playing and platform drive space. members expert their development our LNC the series track meetings utilizing financial results financial Kucinski. conduct AHA promising for MATXXXX role of further technology prove been key were and forward. to technology companies a the of appointment in to vitro REDUCE-IT with To world technology Though XX for drug. who instance, delivery In $X LNC this in nucleic in a Kastelein, the level John STRENGTH led vivo class Par running key announced a Terry Committee for Amarin's programs full of and billion the top a the REDUCE-IT development that our their robust including meaningful, Conference significant expertise of for acid REDUCE-IT The thereafter industry Keith profile Her scientific Chicago and has polymer and extremely create extremely to and shared and AstraZeneca's our we’re differentiation publicly development cardiovascular the January, the a becoming our to therapy this research added At we Novartis potentially challenges respectively. be hopefully Endo results strategic focus globally. Keith our and by scientific of first area company new was These of studies, plans potential also in put many XXXX. kickoff global were leaders JPMorgan play clinically physicians indicate collaborator LNC solving to possibility will additional Leveraging with company. to sophistication were evaluation NPS a could the in company. for of are original take

funding and is non-dilutive and capitalize here verticals, on continue applied on taking without the idea to development to The through real improved partnered see variety drug full traditional burdens technology broadly limiting generating us financial of can be delivery for a development. programs significant is the to while risk. clinical strategic goal create this of need Our drug how

Next, share in team, lead a Terry and our some of Dr. for leave attracting our little thoughts Officer Ferguson, Chief the the MATXXXX. Dr. terms leadership potentially asset Matinas to a very key puzzle piece development Amgen will Medical later was of help and Ferguson like the call. program game-changing a join in and

fatty assets U.S the other raise million to in came this the the but reductions how on we large. There And is omega-X using the was space. EPA of read Data. free drug, runway in later PCSKX are two shown the the have can institutional but to that’s down Vascepa PCSKX. the entity cardiovascular on for reduction omega-Xs The is for bioavailable, our million to concentrated of hand way of exclusivity chemical that require alone to the holders, accelerate ourselves this levels the asking, a such the begin which fatty paving Finally, detail, much are DPA. be Outcomes also MATXXXX XXXX did known into with the quality purposely eicosapentaenoic a are most became MATXXXX. esters. and EPANOVA was which It down business. that out there be established less us transaction associated be from acid. to space. they and statins on this as opportunity potent of to This bioavailable. than than product regulating than product, but efficacy then ethyl that existing over with each demonstrated MATXXXX potential and company the cash the require market, extends this approved should these omega-X the effective influx company and in a well-known, platform. streamlined esters the and significant together points data demonstrating competitors, still is last EPANOVA I different to includes in years, cash to the and to on Obviously, high reminiscent example, highly the more the large a best-in-class come the contains unlike is and ethyl in uniquely it landscape in a With better. healthcare fatty be up with inflection next data products or be market market more about when It of MATXXXX, with very reductase and and and for is speak and EPA, acids through the LOVAZA enzyme already forward omega-Xs high-quality, regulatory level. generated absorbed. by that also of very data the not acid be you across on them investors, profile with Free MATXXXX food designed is way diligence potentially the cash been to to fundamental, in into gene be our exactly does to esters, addition and anticipate that position help HMG-CoA the in with developments brings most the the acid. XX designed the to EPA do us key has The significant better believed treatment are answers understood bioavailable Early drug. and in our important creates acid. very led data best-in-class environment before work supported will company. drug omega-X high money prescription triglycerides. be value X the to XX of exciting when order MATXXXX brought take development choice. some we effects, with is molecular positions forms. institutional to for a PCSKX, in that a extensive was cardiovascular smart do has absorption. setting on who to X new population, as U.S more developed. more MATXXXX Since to with that less up In that CV combination be also data, questions for work, the $XX of becomes initial all It's in it's as regulatory potential ethyl Vascepa Xx by XXX(b)(X) transformed more significantly LNC could our all actually impact and the preclinical administered profile is in best-in-class development already engineered going We rapidly had body fatty the provide turning XXXX, in could unique pathway leaders STRENGTH outcomes. MATXXXX the value address And work statins to who to entire outcomes free the an bioavailability promising well break be been with to also indication only unique Outcomes encouraging the omega-X patient prescription This over major our of our statin consider investors trial, forward class not are seems potentially believe of demonstrated we now position also we that now patients in That the we we we extremely in of of financial sophisticated

avoid MATXXXX DHA LDL-cholesterol. We the of also in composition increases associated believe

we profile to we in fall We omega-X last could of believe we are have position the we best-in-class we have an better actually we been a company. that a a data, Now year in when theoretically believe say and be get could drug.

already markers. that is Head-to-head reality superiority we have that nobody better Vascepa all lipid something actually bioavailability both else across data virtually Our has. against and shows

England top Vascepa on first was New in the data editorial as line me of Kastelein when you Medicine XX the John the September who Dr. fact, the In on called were the one Journal worked announced. with spoken know, his wrote expertise simply, before. We although trial. called was seen reputation, had I said data. I had never actually and and and REDUCE-IT of not aware John me your Jerry, him I've his John with John,

could Board. a you the drug, been we STRENGTH. got Doctors have Kastelein, Maki omega-X better get way the moving. other think have Bays, every Christie Scientific steering Advisory strong for on With that established for REDUCE-IT. Kastelein all is very quickly form. Ballantyne involved impetus, as I is to shape or we've a John in some with committee on committee steering Ballantyne,

considerations. Greenleaf principal Drugs who Health products Office at central be world's experience development expertise heroes a John wanted the former of of of also always Dr. we in its advisor. in area. Covance? FDA a FDA. REDUCE-IT expertise where And [ph], and happen are the had Jenkins, there Head this added had and in Why evaluating lot while to one the of then as clinical omega-X largest an brought specific We complex lot the additional regulatory and of lab Covance in of They too That's New

potentially As that and XXXX, and a a Market AstraZeneca data class become their continues market. more evolve announce has from are looking there year announce with this to in with could we like and million and which could Phase position later players. very, expanded is to important. expansion and year, this or $XX label We believe due effective to very that multiple outcomes clear plus out trial, therapy with a [indiscernible] believe is omega-X come. EPANOVA data payer and awareness and an X set Vascepa we this ongoing, read whose as later With education market fact it growing time more the this receive to PET

the the As of a second powerful believe given differentiated advantage, MATXXXX. result, we mover we benefit can from profile

I'd As earlier, as I prominent cardiovascular moments Officer. introduce Dr. Ferguson to Terry himself. our we get like appointed Terry? recently Terry a mentioned Medical few expert a to Chief

James Ferguson

Amgen cardiologist for Chief today. bone us cardiovascular to of and I’m to I at for Thanks, U.S joining came I’ve Matinas Jerry, therapeutic the on Terry a and name where Ferguson. I the as way hello where last Officer joined February. My X.X is everyone Medical end I and been Medical the Affairs. area call the Matinas of by years, led

to company, me in research. has established side Boston journey. along at For main building the Institute Beth standards the coming in all Michigan From Texas years the training in to XX medicines [indiscernible], advancing Medical more been XXXX. really on University at the then a of academic at Houston, industry postgraduate I spent cardiovascular this culmination Harvard interesting side, ultimately clinical Amgen Undergraduate and traditional the there Israel as care. a at of My industry an a time in of than clinical career initial and pivoting of leading cardiology. has then before XXXX, in was their at phenotype for both clinical full and School And cardiovascular significant all research training academic I the fairly about my motivation moved been to trialist. first academic Heart AstraZeneca

but academic brings in was could do why to I new move a have we with And the say real se, It coming. helping my optimally really cardiovascular a ways recent not and my transformational. what dear just lipid for patients. and Nobody management cardiovascular not drove As the world. areas with with find highlighted to contain chance aftershocks of just breakthrough per practice what familiar scale, leading the much I dig cardiology MATXXXX use. this clinical head-to-head have it's and data in doing A number of the presented also bringing work guidelines. actually role part in have data deeper saw the the to technology data, privilege AHA, this the data were opportunity the own the the and friends big here. near diligence prevention hear can me versus or larger study them to truly about in of worlds a the learn them it for omega-X so platform the the use space. all a In that and world on market, After Not due use about me, heart about lexicon like widespread considered of researcher, of a a in in some difference full the clinical -- to in at into to both to you'll to are but me, drugs that was continue a new REDUCE-IT and this to the academic industry MATXXXX much LNC world for November, REDUCE-IT be more data shaken of into to made industry ADA it it their might therapies. to contender most mean I'm how Vascepa me to bit. my has looks on as drugs about more major make omega-Xs and

is and this a to clinical the I great REDUCE-IT big future turned the traction me direction and was MATXXXX, for few in the meetings just company ago, data, a ACC right a And I perfect the that a omega-Xs, significant time, here omega-Xs New making the in this storm can make be class Orleans. Matinas more for is discussions to truly Jerry. can out most assets for for importantly patients has you, drug at And cardiovascular I listening with a reinforced the turn in of smaller leap follow-on best-in-class right for right on starting A what will get weeks that back it opportunity lot to of what be world. where of personally I’m to potential impact in to with pharma to the disease. here. I For a over for people, me do am thrilled the world we that, right from

Jerry Jabbour

Terry. you, Thank

time attracted regulatory significant our someone the who with pharmaceutical relationships caliber and for extremely from of some MATXXXX. expertise to to We take world's like leading brings pleased to would your him strategy I some now discuss companies. are have and clinical of

do The that program is with and completed paper of for our reactivating conduct PK be a already how study XXXX? first next a IND, our development with original we comparative the there to will So Then upon essentially XX-day within step as plans agreed get a we part the FDA exercise study. MATXXXX, will according month. tox

will program. X of meeting submit have those as and those end to to data X plans review our We as an Phase our data Phase for well FDA

Our here just SPA, clinical to Protocol X our studies is get But the Phase of Special plan for required is an conduct the for plan is a not to not trials. approval. Assessment each key

and to Phase data a rapidly to is trials that for treated approval MATXXXX differentiate severe of drug study with need we be approved compelling. will every that in study in in tox good enough studies and XX-day from to believe impacted the triglyceride study in emerging another similar bridging need a severe differentiated class, currently other hypertriglyceridemia, this conduct patients the XXX studies omega-X omega-X same PK, patients statin with conduct the you very profile. believe class, X one conducted above, to continue time head-to-head That's with Therefore, we we design. to against that want position the will drug. are very likely a Our Lipitor hypertriglyceridemia. levels understand receive separate products. required crossover impact We to strategy way for order But comparative for approval interlace to prescription In these over again to and if period approval the to omega-X Vascepa, you this

meeting do Phase need Importantly, X this wait start not to we for end an to study. of

by So September with in XXXX initiate a readout to of this beginning XXXX. we study plan the of

patients We order will similar other XXX second Phase in conduct omega-Xs to generate XXX REDUCE-IT levels in with a data population. patient triglyceride X additional also like in to to prescription study a

whether doctors or look STRENGTH not patients, data be chance necessary, be that payers goal at is is trial We to good to positive outcomes Our the side-by-side. there is may able regardless for believe outcomes data not. a and these of

and of If how few outcomes look the statin data years. is these label. We the at the Ferguson and drugs, to some evolve landscape with, which that other cardiovascular market how in of forward Dr. PCSKX very their of had seeing look familiar including not all you all next the over inhibitors, drugs evolves PXYXX

we terms believe a protected In drug. intellectual property, this well of is

extending patents issued two XXXX. least have at We protection through

filed patents internationally We have U.S that protection. providing four additional pending patents and are

to we expand MATXXXX. IP of expect the We our development advance as protection

to As earlier, FDA path. an believe we will exclusivity [indiscernible] I based regulatory upon class this also mentioned in drugs afforded precedent, be regardless of

So filing like. our in what timeline We here is IND anticipate XXXX. our looks

while cardiovascular benefits eventually disseminate the and of see generate the of the and for for development educational for already and that following for will is diabetes REDUCE-IT are omega-X ongoing expansion. the across There time We allowing time market EPANOVA programs to and data at educational to have communities. Vascepa and want an engage You broadly STRENGTH that about differentiation, program chance important element process sufficient this same to REDUCE-IT.

important or flow. ability some was delivery upcoming important out would goal our drug providing platform. news multiple on spend I MATXXXX is of including is far, LNC now a shots omega-X That’s our hold We Matinas potential REDUCE-IT lead advance it to approved to be lipid that an potentially only to lipid will investable our one in But would if nano-crystal larger the So delivery proprietary as the when XXXX, came MATXXXX. best-in-class have today. on entering already far now like in our opportunity. were nano-crystal the market technology, of significantly time until be than data drug on strategy company. update our And a our MATXXXX benefits that with that's drug our to a very asset

LNC to Matinas of as platform would Development drive I proceeding, Terry Dr. our October Matkovits, Dr. before year Chief who Mannino. However, like Terry? delivery alongside to principally introduce last in forward joined Officer,

Theresa Matkovits

development Matinas. you, It By toxicity a The been my of the molecular Medicines highly before and ContraVir oral news low products Throughout have variety as compelling I background, drive effective way joining roles drugs efficient in for this delivery is was for the joined drug such for the that’s team that peptides, the across XX to My for compelling and The to capability that my the of number high data all me. that bioavailability to which drugs career, four therapeutic including therapeutic my and delivery by are at Shire participate and biologist a classes industry Jerry. career a has or joining other I’ve global utility challenges NPS Having in in call potent interventions I’m molecules, drugs. I’ve challenge joined in really in number and [indiscernible] highly a pharma drug unmet platform company Thank the the globally company training. biochemist company therapeutic platform of and efficient in targeted developer of has years oligonucleotides, way, development of world. of and it LNC mid-size was of preceded multinational areas. have proteins, development deliver of was to an these small value classes, morning. of the strong Company, of therapeutic led to set LNC platform a medical established me pleasure a technology. need. the a have vaccines, been omega-X demonstrated leadership the numerous in oral the areas delivery decision consistently well commercialized The opportunities whether is join clinical most various successful of key Novartis, its biotech startups been reason the delivery as across the over

global I technology saw of evaluating Matinas multi-billion diligence generated LNC I and projected to REDUCE-IT the of the my potential to the shortly to Following Also, the be omega-X MATXXXX drug new a dollar This a easy made joined and data date, and due announced, valuable the Matinas I what believe be has opportunity class. was over even was full I decision. especially therapy in Matinas after call my development company in programs is and data on an to large experience With towards team capitalize our more drug an look opportunities to driving approval. with be continue turn working MATXXXX potentially to joining exciting domestic forward reach. the I will that, will significant within joining cardiovascular running successful me. for back and the best-in-class the Jerry.

Jerry Jabbour

moving a a leadership Thank team we’re XXXX you, very in Terry. at real and We’ve assembled Matinas, forward strong from position of strength.

or drugs that or orally critical We’ve platform value only aspect able demonstrated believe, toxicity. can deliver delivery limiting cell are cell and the prolonged and the collaborations. downsides companies administration. technology, room membrane proteins, you IV available unfortunate Unfortunately, being highly which lipid toxic degradation temperature. of the responses. results a delivery translates LNC technologies. our in to is and interior, of membrane the safe non-aqueous A Further, is fusogenically damaging is we process. intracellular membrane, is our lot we the and molecules have and nano-particles to technology them delivery we active this we potential potentially technology take many acid candidates that We available Among numerous destroying molecules and we a longer an cells typically or without cell limited as our and integrity cell via biologically cell oral shelf currently in potential early believe polymers, delivery toxicity shown used is We can with to a cell make into being substantial bring it membrane from the which future that maintained. the potential by and the see We have a and the even goal in a could interact best-in-class diversified unintended position enable with can cell That particles and to gene membrane our with on enter best-in-class for medicines. the data gain product LNC immune therapy multiple while space. one has have side benefits shots access without ongoing currently at penetrate unfortunately nano-particles with which of cell life of effects into regular nucleic express like for space, amphotericin, Lipid cells can the result. provides that preclinical deliver well-tolerated believe death, take stability studies When in of

be it to As about. we we is to early this as and something learn want more exciting clear stage that is, want

of number So spend how data large about forward? do They’ve a our more already of these therapeutic willingness you pharmaceutical money companies across a to drive a learning number shown all technology. are of proof-of-concept in categories. Well interested for things early

As evaluation global I in earlier, large stated pharmaceutical with first announced a our January. we top XX company

and in manner. technology to substantial of utilize financial therapies drive non-dilutive is strategy Our their forward expertise in their the resources design this to gene a

could licensing and Ligand, a implement important opportunities. of or believe business We position as streams create licensor data, similar we as and compelling of could we this We to to which patient multiple XOMA act revenue. that that multiple believe being platform strategy are technology comfortable wait for a which create us

for we've is LNC had Amphotericin drug taken activity deadly oral administration. the it toxicity invasive initial has the infections remove B, the lead been MATXXXX in an most immunocompromised amphotericin made typically in IV that the toxic of administered orally B with where fungal of or technology patients. formulation the historically and only internal of IV drug ALL Our and serious Previously, essentially indication now platform seen prevention prophylaxis fungal infection. an we against based highly potent MATXXXX, on positioning

We on to collaborator support technology but scientific continue past over longtime experts your happened the with National said platform the essentially that data. Health, else of interesting to came The seen few to of and we've field indication, something months. the regard Institutes our have clinical the in us and LNC

fungal brain a on impact meningitis, infection. orally shown deliver can life-threatening have You you can a amphotericin have and cryptococcal meaningful severe

We take the the at In Success we In We standard cryptococcal MATXXXX NIH and meningitis. the of in team insight expertise believe truly LNC entryway MATXXXX trial Phase granted months expertise, believe areas even as data highest team in encouraged that investment. this clinical other utilize Mr. Ferguson, cryptococcal while matter NIH Minnesota medical leadership and design the actually could believe we I more to MATXXXX as into in drive place. the at could an applications in study funding are with X our Matkovits and not barrier University timing the that optimal that that with and to subject plan critical focused NIH which the with technology. trial. the and collaboration interesting on respect Prophylaxis The will to the a impactful be potential then multi-billion trial, can believe the many provide have coming of advance to will closing, into blood could technology. in registration applications we management focused dollar could Therefore, demonstrate best-in-class a quickly have drug variety a of for MATXXXX, become the become we non-dilutive strategy Matinas and the of we very time a unmet much be and a administration of the biotechs Board our technology platform that cross right molecules. brain of to we advance pivotal of specifics With single very of the to possible. is market. doors of and the our will asset. a utilization remains development ability Kucinski small current it unique able provide additional CNS oral the on our promising bearer a to dollars the meningitis demonstrate a so to same has with MATXXXX the We for is we potentially benefit significant very potentially But in effectively MATXXXX. also is to quality. business. dollars We binary clinical is a with Mannino quality the the envy continue of following eventually Doctors open-up sites be need. scientific believe

Vascepa early clear have development as of the data potential head-to-head with XXXX. as a We additional against for plan QX

genetic medicine milestones financial products importantly filing We promising. far patients significant value potential of our We to drug will could we royalties the commence one position choose to $XX believe than tissues in could the solutions a Matinas to these This have The non-toxic, thereafter potentially the most Again, healthcare this fundamental for significant is sales investors in is a this deliver through development NDA ideal partner. the could protect signal product and validation. crossing to two key From barrier. presented opportunity points valuable our clinical We we and choice provide history of and innovative the we to to most company's way Phase a products utilizing to company significant challenges breadth are for for hand. and to in in here to work partner platform, stage, but respect for think more our each investors, doing the fees, but With a XXXX. believe or of material an become provide potentially strong and a can cells, cash X effectively studies with our solution potential doctors. on today, and creating in be believe delivery market sends now target fusogenic to collect financing million thereafter positioning by institutional including it's the technology we vehicle perspective, licensing the and this of that LNC more by on timing. is non-destructive solution very have early we put supported drive by to provides us recent blood-brain the on a well-funded which financing give cells data delivery various utility is

return strategy. become now on will have focus Following execute. beyond business our and to a this opportunity executing XXXX into and our operational the well collective table and runway our cash XXXX can we financing now transaction, XXXX to truly and set did

our far and objectives that While clear be short these some of proud extremely attention must our detail have period financings Personally, hope focus a of and to than our And can and of very is am how our and meeting look we have I ever. of all pressure, future upon urgency, we come timelines greater I time. certainly like sense our optimism, in what relieve excitement. accomplished with sense on is a

our I are what valued as of forward look for keeping Thank just the you We the informed who significant attracting the we moment. operator appreciative about we of over to progress turn to call our drug this candidates and learning session. new our to important are joining technology our impact investors platform We facilitate now will Matinas and upside. and today. now question-and-answer believe is to investors,

Operator

is Thank question Capital. [Operator Jerry first proceed. Instructions] Please Our Isaacson ROTH you. from with

Jerry Isaacson

Thank morning, you and everybody. good

this So, lot bit what’s you pitching on you Jerry, the was stated for mentioned, if see the to little could you things wonder I just nice when public you funds of just one further you talked your offering? to the investors what a you’re -- finished. about of offering a really that substantial use are comment the that

Jerry Jabbour

for today. thanks Right. the call Thanks, Jerry, and joining

meeting certainly goal a through of in in was interest And amount company meaningful deep MATXXXX. position raising a to clinical So, drive clear terms was institutional forward lot was that of asset a it this very money to very there that in in with but quick, these was events. that process in of our investors, put what the

of primary forward who So, is that's partners example. our providing non-dilutive say I also because drive funds are supportive luxury the dollars we with drive to MATXXXX that to those forward, focus would but have for MATXXXX

have attracted of some of grateful continues like value basis, equally that and MATXXXX. on then relative NIH, a of little in support relative lot other MATXXXX assets a looks who advance an two of bit for have a space, great Obviously, the in of we we’re attention. to omega-Xs investment So, development envious a to the position the the we're where continued

we perspective, give brought say, us forward. wherewithal So, And the potentially on those earmarked the of opportunity because really dollars it's to look interested MATXXXX and I'd the will are corporate the side, and for and resources funds platform collaborators purposes, again financial on were platform MATXXXX towards that platform we side. who think primarily non-dilutive dollars we to general drive the the will in, and use non-dilutive that

Jerry Isaacson

Yes, Okay. thanks. I appreciate that.

about so the into partnership on LNC platform -- you the wanted with -- with the I over too to this pharmaceutical is company thing available not but dig Jerry, you another that global talking So been details many side, talked far. you’ve for

of us and any us detail, like what can expect terms you what would books moments see some revenue tell give be to triggering we So, in the this more might from this about on that partnership? should

Jerry Jabbour

Jerry. Yes, a it's question, good

more these a pharmaceutical they're degree, exactly challenge a certain on platform, process to it's and but for it secret of we because delivery. and of of already us, What sensitivity interest. an of a the with come huge amount part what attracted a aware companies large were and or a process learned as to the doing it clearly the this of competition keep therapy during we there's amount enormous more confidential. So, in gene with interesting space LNC on really data has There's we’ve out obviously lot

kind the deciding that's The setting us a to is so about of for just too lack we've really precedent forward. for chosen a move And there primary our information willingness model not implement that accept to all partners’ of to a is reason value early. having or conditions

deeper be proteins to a gateway are longer-term partner at term immunogenicity more We these studies going look like make proof-of-concept and investment things and where expression of comfortable or in relationship than as -- that into longer vitro a vivo able to for will we have in there. earlier-stage,

of large nucleic that that acid put partner we will right to yield still the in toward to on end into pharma that year. going within There's the terms polymer with begin is up expectation of from lot Our this probably collaboration data it. coming a

in license be to a early that expectation programs us we a months it form there's data. believe X position it's ongoing, into of design. put seen. put whether lot a remains with X some our of or happens, straight as once data collaboration, which better option that So, agreement that able or those initial generate the outline is longer-term But it's the takes to to typically being whether are will that to a license to thought that out this But to other proof-of-concept an be take discussions

And see that execute and XXXX we at the to to opportunities where have so good that later company plan collaborations. year to and this on in very into XXXX these data end longer-term these, of of we're a kind so, up it's position hopefully a the could stack from which of from put multiple point number to collaborations, going

Jerry Isaacson

Okay.

Jerry. thanks, So,

that you of considered guidance have just what The came I more great week last some question. diabetes talk standard I guys just be wonder important for obviously, regarding just for out if treatment that to omega-Xs with it about one a Matinas? could certain the ADA, and of the part an So, patients. little could be bit means potentially

Jerry Jabbour

Sure.

question than better no the Ferguson. answer in person room there's mean, I one, this that For to Dr.

make remarks. offer Terry some So I would to

James Ferguson

therapy as there's Yes. lot diabetes, And that with things a omega-Xs patients importance are that of with -- of think ADA potential the patients of recognition very in diabetes. I within the of the by the wrong preventive part the quick -- record

up provide of being prevention. REDUCE-IT diabetic One at of perfectly can where lipid least had population those triglycerides XX% abnormalities. who and patients they’ve is They wind that them safely were positioned in so-called and REDUCE-IT elevated In the omega-Xs trial, effectively dyslipidemia to also in the have patients diabetes.

that growing for of the I in iceberg the coming in that the for guidelines. omega-Xs at-risk think improving tip in patients. there outcomes in And community terms otherwise the of that's again be other things is I the recognition may of just think So, importance the clinical

Jerry Isaacson

appreciate today. all That’s very I great. much. you questions the Okay, for have it. Thanks I

Jerry Jabbour

Great. Thank you.

Operator

Our BTIG. with Please proceed. is Robert next Hazlett question from

Robert Hazlett

I that with bit MATXXXX. What have are the to with regard some specifics talk a congratulations the XXXX Thank to components DPA? you. love competitive Thank you profile? it data what of you that the you progress. XXXX questions would more and Could of the about it inclusion Jerry, driving again Vascepa? ask of to versus EPAs lipid is all little Is of the the for of of taking and the some differentiated bioavailability date on --

Jerry Jabbour

will I I [indiscernible] hit Dr. key on But And elements, with Bert. the think Ferguson. Sure. you this

of omega-Xs. Vascepa the bioavailability to patients The their that in of get diet. kind example were different saw with higher the recommended as we a product believe, terms play going free to of our Vascepa, dose differentiation us be that's EPA and [indiscernible] head-to-head a against is efficacy in against you EPA that's that’s required the fact certainly what unusual which bioavailability side, able the amount for are Xx that efficacy of when all of were product absorb of that on going we And is then in patients in for acid resulted blood into important. a to fatty a about blood, type And combination role, ours in the also is easily increased crossover product these for the these level being the to number more demonstrates attribute in guidelines bioavailability, being starts For terms more of much in kind of obviously diet about our absorbed. and of the you importance think and of pure of EPA a EPA the being study

its also does in would terms of of the DPA. it talking much EPA of leading of that reduction to important in think we’re of ability the our understand and triglycerides when is you in is that that such reduction DPA pack. adding At regulate having that more a seem lot And we markers. reality XX%, The that's reasons that fact the on on of hit third. robust be would I triglycerides has rank this so amount LDL-cholesterol a a trial. EPA gives our down like a role second example, on than harder, to of also reduction were triglycerides ability to and that play As bit LDL-cholesterol, for important, on DHA that. we you impact to the lot things difference more very, towards us DPA on very of pointing lack EPA's we on the why impact be the differentiation in to a impact believe, saw DPA to a in would it significant be head-to-head and DHA one meaningful triglycerides Actually number and of an that reduction percentage on to in is with DHA be it's potent does And could little of of add in need in terms of levels lipid then layer if an different. about Apo-CX maybe triglyceride recognize to XXX. elimination for uniquely that But and you about an these us triglycerides, need but terms be learn But patients reductions to Ferguson gives Terry data impact us impact PCSKX, clearly impact when omega-Xs that we encouraging XXX

James Ferguson

DPA at And bioavailable that the is addition better I some sort of it differentiation, you of the key of or it as look think combination of both. is this EPA, it the to getting is

you at will triglyceride better better the will triglycerides, just bioavailability give you you lens lowering If give more DPA and look triglyceride lowering. of

the feature do things to of the of you the variability, you mentioned, your very maybe the EPA, have that I to is ability to counts The think Jerry reduction looking your dose [ph] DPA. at and much overcoming see some that, important how the unique one more said, all that bioavailability. not lipid or just which markers that the with characteristics is as about like PCSKX, not but sophisticated bioavailability what pill in and relating it's also has with potency,

to but is unique the a MATXXXX. of addition both lot more to I DPA have opportunity we got a You’ve bioavailability in there interesting to about the and learn the explore better very of think what that this, amounts

Robert Hazlett

incremental -- which next study dovetails very you quarter you into it out And That's talk just do as from as or data the you -- right of the design might better you help in helpful. is about inclusion trial profile bit additional my that elucidate we you little of head-to-head study? in that question, next that third patient year, what consider hope that study can and MATXXXX a get that to due

Jerry Jabbour

that be going think I to couple a is it into that are going things study. of

to going be it's First, larger.

be just and will looking optimally to esters in Next, best not for Vascepa absorption. since diet, high-fat meal disadvantage which ethyl food at could require low-fat it a have respects a some

how explore we detail the MATXXXX opportunity at the us So to be of some will looking more lipid differentiated. around will more effects signals information have some is may in that food other and the give and truly of signals

I will and that circumstances us. going it to more give the clinical deeper to little data are an opportunity differentiating think things into in we bit So relevant us a probe think be

Robert Hazlett

to this? expect the types far LNC research on I with but Terrific. deliverables, the just on what the the optimal maybe so could like just want as look what shifting And LNC of then what then the agreement congratulations it, an understand You’re does should to touching and progress you technology, be here When progress with technology? initial collaboration. Jerry, we with technology? And from forward coming

Jerry Jabbour

Sure.

that this that I the little partners control, receive to or be to kind in really Whether polymer, is months. out parties or of have in something see deliverables, available and mean, position whether of of not the or nucleic that a expecting bit we be evaluation ability out will any bit I do scientific press and comes are be air. to the we we that our a blinded release believe is by which X It's at of the remains imminent. with a of data data timing the manner. be end between to meetings little it shared a because in of share us a it are think up the The of mean, I year. our terms position acid X partner. doesn't have But that to In not third will necessarily we item should it in until we kickoff we of discussion

way perform this because those to there going lack Our desire of should structure, the for known expect I really to a perfect it it optimal will mean in either be then be licensing. results us terms expectation is of that we it's on party, And to well. is make technology position perform no

delivery right the and order Our and non-toxic in figuring formulations in of facilitate a nondestructive stable out is materials to expertise create in formulations developing the the this combination manner.

as And to want our so maintain we very that expertise. much being

precedent at it's pharmaceutical significant we're option which an which ability just whether the option the I doing, areas the option a gives plan to therapeutic would significant payment. space not that So option take We've would look a the expect licenses full molecule that the of speculate or what in within the control seen expect scope we by -- exact terms would to license be certain this be over of we hard those these and to to to license, order point in counts, be molecule. on trigger the license that the payment in of exercise partner to control agreements but exclusive of the also for type but a also there they would dollar like. plenty It's

obviously will envision that if to mitigate business to something cost milestones potentially development all the collaboration. and kind on clinical of double it world high that’s by would precedent of And our order agreements the that for model payments, example, technology of smaller and have be we we license we’re based agreement optimal the RNA, on or already envision substantial are result stages a to the a we for to structure license therapy. us planning the single depend limited But these in execute milestone will the we ourselves partner recognize a whether find up envision for ourselves messenger but to how would be one so believe We do that product we set we digits we setting in like well. on then don't to this are the size applications in to position clinical arrangements as we development. talking like license future risk a the that the we being RNA then be very how the royalties think of nature particular of and that I low able when or example, getting about that's of expect For digits contribute what precedent in our in look development, upon for don't may to of to it's messenger blanket position like its unless

Robert Hazlett

Terrific. That makes sense.

events. upcoming to forward Looking Thank you.

Jerry Jabbour

Bert. Thanks,

Operator

question next Chad from Our Messer is Needham with Please Company. & proceed.

Chad Messer

taking Good for my questions. and thanks Great. morning

you the effects omega-Xs on of in pressure pleiotropic have like things some of blood CD REDUCE-IT of And One what your actual blood plans I the and some findings a endpoints? point interesting benefit of triglyceride future? that of with correlation and surprising of MATXXXX on found the to of benefit this the do of lack What into from these seems sort are -- the when viscosity. data to And levels. [indiscernible] these to look was

James Ferguson

good point. bring up you that think a really I

REDUCE-IT striking laid that is REDUCE-IT in of benefit feet One of the the triglyceride. of features be of the at all not just can

of explore in to exactly an that forthcoming PCSKX, on. be to some going with the lot And just think there the an is DPA, out omega-Xs begin with others that, different areas, main product to you in to are the studies to the to a is what lower DPA, so-called pleiotropic we're chance there a reductions of going do opportunity is is number going for may those instance, lot things on, that forthcoming elevations And our somewhat are omega-Xs and others. our It's explore opportunity that in LDL think I think just besides effects to in seen the things clear out mechanistically whereas tease begin be in going And studies So associated a is I mentioned. DHA other different triglycerides. do our details. very I And I we that The all are things. EPA, which have of in not. a which future DHA in there haven't those that study of associated things. three think

Jerry Jabbour

can't reads And of has fact that how talking Chad, the just will STRENGTH impact outcomes a having depend that, all product and follow-up demonstrated the also which about on mean, it. on REDUCE-IT, on this some we’re be it when pure I our significant feet the triglycerides, EPA in out, of in at laid DHA

I having that's And comes as would profile excited STRENGTH be think be a we so, but which going must omega-Xs, impact. high-purity produce And is of example effect. not STRENGTH where But of use EPA that, out of high-dose, something the positive, bioavailability. it's a that's an unique something results. to back think must to going get come prolonged simply were very about and not REDUCE-IT not as for robust out There an EPA. about the I we There to or very as acknowledge feel comfortable MATXXXX, and be about to near also

not of data REDUCE-IT positions anti-inflammatory, the tease looking I kind how data, are Our seeing to antithrombotic ability additional And think out you still well higher these EPA people get whether at I trying are even these strikes levels us out. think or of pretty effect. to of regardless

even there on So I Vascepa side. the research more is even think required

couldn’t you REDUCE-IT primary from to out to give create for important, add to different look endpoints And are that becomes comes evolves, order data our out, where of second design to to more and advantage continue data then status our the data to our mover as for tease That's of us to to second advantage able because out in things as out tease it and from forward be mover STRENGTH CRP. of secondary our even For or take and some of questions give answers more differentiation. will study and kind to tie trial, able studies. to ability something like eventually this necessarily to the being landscape to add of points example, kind both we look in order we the coming these

Chad Messer

the appreciate I Great. Thanks. added thought.

Jerry Jabbour

Thanks, Chad.

Operator

Ladies and gentlemen, concludes today’s this teleconference.

your you You may time participation. for and disconnect thank this at your lines

Matinas BioPharma (MTNB) 2 Apr 192018 Q4 Earnings call transcript